AUTHORS
Jesse Fajnzylber, MD, MS, Kari G Rabe, MS2, Paul J. Hampel, MD3, Lindsey Elizabeth Roeker, MD4, Yucai Wang, MD, PhD5, Mazie Tsang, MD, MAS, MS6, Ricardo Daniel Parrondo, MD7, Rachel J. Bailen, PharmD8, Amber B Koehler, PA-C9, Amy L. Behnken10, Talal Hilal, MD11, Sikander Ailawadhi, MD12, Allison C Rosenthal, DO13, Cinthya J Zepeda Mendoza14, Rebecca L. King, MD15, Curtis A. Hanson, MD16, Esteban Braggio, PhD17, Susan L. Slager, PhD18, Min Shi, M.D.19, Saad Kenderian, M.B., Ch.B.20, Neil E Kay, M.D.21, Sameer A. Parikh, MBBS22
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic Arizona, Phoenix, Arizona, United States
7 Mayo Clinic Florida, Jacksonville, Florida, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic Arizona, Phoenix, Arizona, United States
12 Mayo Clinic Florida, Jacksonville, Florida, United States
13 Mayo Clinic Arizona, Phoenix, Arizona, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic Arizona, Phoenix, Arizona, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background:
According to the Surveillance and Epidemiology End Results (SEER) database, the median age of CLL diagnosis is 71 years (yrs), with approximately 10% diagnosed ≤55 yrs. Bruton tyrosine kinase inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have improved overall survival (OS) for CLL patients ≥65 yrs, bringing OS to a level comparable to that of the general population without CLL. Whether similar gains in OS have extended to younger patients in the targeted therapy era is unknown. We conducted a retrospective study to compare the outcomes of CLL patients diagnosed at age ≤55 yrs between 2014-2026 (targeted therapy era) and 1995-2013 (chemoimmunotherapy era) at Mayo Clinic in Rochester, MN, each benchmarked to the general population.
Methods:
Patients with a diagnosis of high count monoclonal B cell lymphocytosis (MBL), CLL, and small lymphocytic lymphoma (SLL) at ≤55 yrs who were seen at Mayo Clinic from 1995-2026 were included in this study. Patients were grouped based on yrs of diagnosis (1995-2013 vs 2014-2026). Baseline demographic and clinical characteristics, prognostic variables, and treatments were abstracted from the medical records. Clinical characteristics and outcomes of patients were compared between the two groups. Time to first treatment (TTFT) was analyzed using the Aalen-Johansen estimator accounting for competing risk of death. OS was analyzed using the Kaplan-Meier method. Association of diagnosis era (1995-2013 vs 2014-2026) with TTFT and OS was analyzed in multivariable Cox regression models, with results reported as hazard ratios (HR) and 95% confidence intervals (95% CI). Observed survival in CLL patients was compared to expected survival, estimated using the age- and sex- matched reference population of the state of Minnesota. The Mayo Clinic Institutional Review Board approved this study.
Results:
A total of 1,778 patients ≤55 yrs (median 50 yrs, range 21-55) were diagnosed with MBL/CLL/SLL between 1995-2026 (114 with high count MBL, 1,436 with CLL, and 228 with SLL; hereafter collectively referred to as CLL). Of those, 1,182 patients were diagnosed between 1995-2013 and 596 between 2014-2026, both with a median age of 50 yrs (both ranges 21-55). The 2014-2026 cohort had more females (40.4% vs. 33.1%, p=0.002), were more likely to have Rai Stage 0 disease (58.8% vs. 52.2%, p<0.001), and have IGHV mutated genes (53.6% vs. 46.6%, p=0.03). There were no significant differences in CLL FISH profile, CLL-IPI risk scores, and TP53 aberrations between the two cohorts.
Median follow-up for all patients was 17.1 yrs. In the 1995-2013 cohort, median follow-up was 16.8 yrs, 709 patients had received CLL-directed treatment, and 456 patients had died of all causes. In the 2014-2026 cohort, median follow-up was 4.8 yrs, 248 patients had received treatment for CLL, and 35 patients had died of all causes.
The median TTFT did not differ between the cohorts in univariable analysis (both 4.7 yrs, p=0.97). CLL patients diagnosed at ≤55 yrs had a significantly shorter OS compared to the age- and sex-matched OS of the reference population of the state of Minnesota (HR 3.9, 95% CI 3.6-4.2, p<0.001). By era of diagnosis, both cohorts had increased mortality compared to age- and sex- matched controls: 1995-2013 (HR 4.0, 95% CI 3.7-4.4, p<0.001) and 2014-2026 (HR 2.7, 95% CI 1.9-3.7, p<0.001). The 2014-2026 cohort had longer OS compared to the 1995-2013 cohort (median not reached vs. 20.5 yrs, p=0.01). After adjusting for age, sex, initial diagnosis (i.e., CLL/SLL vs MBL), Rai stage, and IGHV mutation status (n=1,027 patients with available data), the 2014-2026 cohort had shorter TTFT (HR 1.22, 95% CI 1.01-1.48, p=0.04) and longer OS (HR 0.60, 95% CI 0.37-0.98, p=0.04) compared to the 1995-2013 cohort.
Conclusion:
With the therapeutic landscape shifting from chemoimmunotherapy to targeted therapy, our study is the first comprehensive analysis describing the impact of this shift on the survival of younger CLL patients. We found that although OS has improved in younger CLL patients diagnosed in 2014 or later (the targeted therapy era), a mortality disparity persists between younger patients with CLL and age- and sex-matched general population in the targeted therapy era. This underscores the need for further research and improved therapeutic strategies for people diagnosed with early-onset CLL.
DISCLOSURES
Jesse Fajnzylber, MD, MS: No relevant conflicts of interest to declare.